Inactive Instrument

Roche Holding Ltd. Share Price Swiss Exchange

Equities

CH0012032048

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for Roche Holding Ltd.

Financials

Sales 2024 * 60.04B 65.29B 5,227B Sales 2025 * 63.8B 69.39B 5,555B Capitalization 178B 194B 15,500B
Net income 2024 * 13.27B 14.43B 1,155B Net income 2025 * 14.75B 16.04B 1,284B EV / Sales 2024 * 3.2 x
Net Debt 2024 * 14.24B 15.49B 1,240B Net Debt 2025 * 8.17B 8.88B 711B EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.7 x
Employees -
Yield 2024 *
4.41%
Yield 2025 *
4.56%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 66 31/12/95
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company